Ambrilia Starts Prostate Cancer Trial

Ambrilia Biopharma has initiated a Phase I/II trial for goserelin in patients with hormone-sensitive prostate cancer.

The product is an injectable formulation of the three-month release version of Zoladex, a luteinizing hormone-releasing hormone analogue indicated for hormone-sensitive prostate cancer as well as gynecological indications such as fibro-myomas and endometriosis, Ambrilia said.

The multicenter study will assess the hormonal efficacy, pharmacokinetics and safety of the drug.